Article

Case 2: Same patient with more severe DME and history of cardiovascular events

Hear about the case, view the slides, and vote on your responses.

Download all slides for case 2, click here.

Next page

 

Continue, next page

 

 

Continue, next page

 

Continue, next page

 

Download all slides for case 2, click here.

Back to the Management and Treatment of Diabetic Macular Edema main page

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
Related Content
Assessment of AI-enabled screening for ROP in low-resource settings
May 8th 2025

Assessment of AI-enabled screening for ROP in low-resource settings

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Galimedix Therapeutics completes single ascending dose portion of phase 1 trial assessing GAL-101
May 8th 2025

Galimedix Therapeutics completes single ascending dose portion of phase 1 trial assessing GAL-101

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Topcon announces launch of IDHea
May 7th 2025

Topcon announces launch of IDHea

Phase 2 BETTER trial results shared at ARVO 2025
May 7th 2025

Phase 2 BETTER trial results shared at ARVO 2025

© 2025 MJH Life Sciences

All rights reserved.